Combined effect of teriparatide and an anti-RANKL monoclonal antibody on bone defect regeneration in mice with glucocorticoid-induced osteoporosis.

[1]  Sakae Tanaka,et al.  Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial , 2019, Annals of the rheumatic diseases.

[2]  T. Gardella,et al.  Parathyroid hormone(1–34) and its analogs differentially modulate osteoblastic Rankl expression via PKA/SIK2/SIK3 and PP1/PP2A–CRTC3 signaling , 2018, The Journal of Biological Chemistry.

[3]  M. Akhter,et al.  Glucocorticoid-induced delayed fracture healing and impaired bone biomechanical properties in mice , 2018, Clinical interventions in aging.

[4]  L. Hofbauer,et al.  Glucocorticoids suppress Wnt16 expression in osteoblasts in vitro and in vivo , 2018, Scientific Reports.

[5]  P. Geusens,et al.  Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. , 2018, The lancet. Diabetes & endocrinology.

[6]  J. Compston.  Glucocorticoid-induced osteoporosis: an update , 2018, Endocrine.

[7]  H. Akiyama,et al.  Osteoblastic heparan sulfate regulates osteoprotegerin function and bone mass. , 2018, JCI insight.

[8]  E. Deeks.  Denosumab: A Review in Postmenopausal Osteoporosis , 2018, Drugs & Aging.

[9]  P. Geusens,et al.  Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial , 2017, The Lancet.

[10]  Raveendhara R. Bannuru,et al.  American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis , 2017 .

[11]  Y. Fujiwara,et al.  Cortical bone loss caused by glucocorticoid excess requires RANKL production by osteocytes and is associated with reduced OPG expression in mice. , 2016, American journal of physiology. Endocrinology and metabolism.

[12]  Changyong Wang,et al.  Deubiquitinase MYSM1 Is Essential for Normal Bone Formation and Mesenchymal Stem Cell Differentiation , 2016, Scientific Reports.

[13]  Takeshi Matsumoto,et al.  Individual and combined effects of noise-like whole-body vibration and parathyroid hormone treatment on bone defect repair in ovariectomized mice , 2016, Proceedings of the Institution of Mechanical Engineers. Part H, Journal of engineering in medicine.

[14]  H. Genant,et al.  Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose–response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)—a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II , 2015, Annals of the rheumatic diseases.

[15]  Y. Kadono,et al.  Individual and combining effects of anti-RANKL monoclonal antibody and teriparatide in ovariectomized mice , 2015, Bone reports.

[16]  Alexander Rauch,et al.  Instructions for producing a mouse model of glucocorticoid-induced osteoporosis. , 2014, BoneKEy reports.

[17]  R. Rizzoli,et al.  The role of teriparatide in sequential and combination therapy of osteoporosis. , 2014, Swiss medical weekly.

[18]  Hang Lee,et al.  Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial , 2013, The Lancet.

[19]  S. Nutt,et al.  M-CSF instructs myeloid lineage fate in single haematopoietic stem cells , 2013, Nature.

[20]  Xianrong Zhang,et al.  Mesenchymal progenitors residing close to the bone surface are functionally distinct from those in the central bone marrow. , 2013, Bone.

[21]  J. Kanis,et al.  Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[22]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[23]  M. Almeida,et al.  Glucocorticoids and Tumor Necrosis Factor α Increase Oxidative Stress and Suppress Wnt Protein Signaling in Osteoblasts* , 2011, The Journal of Biological Chemistry.

[24]  Sakae Tanaka,et al.  Increased bone mass in mice after single injection of anti-receptor activator of nuclear factor-kappaB ligand-neutralizing antibody: evidence for bone anabolic effect of parathyroid hormone in mice with few osteoclasts. , 2011, The Journal of biological chemistry.

[25]  Yingze Zhang,et al.  Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model. , 2011, Bone.

[26]  Y. Tabata,et al.  Biomechanical evaluation of regenerating long bone by nanoindentation , 2011, Journal of materials science. Materials in medicine.

[27]  Jean-Pierre Devogelaer,et al.  Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. , 2009, Arthritis and rheumatism.

[28]  Thomas A Einhorn,et al.  Comparison of Effects of the Bisphosphonate Alendronate Versus the RANKL Inhibitor Denosumab on Murine Fracture Healing , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[29]  Mary L Bouxsein,et al.  Age‐Related Changes in Trabecular Architecture Differ in Female and Male C57BL/6J Mice , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[30]  J. Williams,et al.  Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells. , 2006, Bone.

[31]  D. Donley,et al.  Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the fracture prevention trial. , 2005, The Journal of clinical endocrinology and metabolism.

[32]  G. Pharr,et al.  Measurement of hardness and elastic modulus by instrumented indentation: Advances in understanding and refinements to methodology , 2004 .

[33]  E. Mackie,et al.  Establishment of a Model of Cortical Bone Repair in Mice , 2003, Calcified Tissue International.

[34]  M. Bostrom,et al.  Systemic corticosteroids inhibit bone healing in a rabbit ulnar osteotomy model , 2000, Acta orthopaedica Scandinavica.

[35]  R. Lindsay,et al.  Anabolic actions of parathyroid hormone on bone. , 1993, Endocrine reviews.

[36]  Ronghan Liu,et al.  Clinical Application of Teriparatide in Fracture Prevention: A Systematic Review , 2019, JBJS reviews.

[37]  H. Yoshikawa,et al.  The combined effects of Teriparatide and Anti-RANKL Monoclonal Antibody on Bone Defect Regeneration in Ovariectomized Mice. , 2019, Bone.

[38]  H. Yoshikawa,et al.  Effects of single or combination therapy of teriparatide and anti-RANKL monoclonal antibody on bone defect regeneration in mice. , 2018, Bone.

[39]  Sumiko Kawai,et al.  Effect of three types of mixed anesthetic agents alternate to ketamine in mice. , 2011, Experimental animals.

[40]  J. Fricain,et al.  Drilled Hole Defects in Mouse Femur as Models of Intramembranous Cortical and Cancellous Bone Regeneration , 2009, Calcified Tissue International.

[41]  Y. Shimada,et al.  Intermittent administration of human parathyroid hormone enhances bone formation and union at the site of cancellous bone osteotomy in normal and ovariectomized rats. , 2008, Bone.

[42]  E. Bonucci,et al.  Bone loss in response to long-term glucocorticoid therapy. , 1990, Bone and mineral.